PTH and hypercalcemia disease: In clinical practice <i>CYP24A1</i> loss-of-function mutations should be considered in patients presenting with PTH-independent hypercalcemia, hypercalciuria, and 1,25(OH)2D levels in the upper normal or elevated range.